By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company. AbbVie’s mission is to apply the expertise, dedication, and creativity of its people to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products — Imbruvica®, Venclexta™, and Empliciti™ — and a pipeline containing multiple promising new molecules that are being studied in nearly 200 clinical trials in 19 different types of cancer.

AbbVie is expanding its oncology hub on the West Coast, with three sites in the San Francisco Bay Area (Redwood City, South San Francisco, and Sunnyvale) focused on the discovery and development of novel oncology therapies. More than 1,000 AbbVie scientists, clinicians, and product developers with strong entrepreneurial roots work across these three sites. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments.




CEO: Richard A. Gonzalez

CFO: William J. Chase


Please click here for Abbvie job opportunities.


Please click here for clinical trial information..


Key Statistics

Ownership: Public

Web Site: AbbVie
Symbol: ABBV

Company News
AbbVie (ABBV): A Wonderful Company But At What Price? 6/21/2017 6:17:21 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
Why AbbVie (ABBV) Is A 'Trump Stock' 6/14/2017 6:07:05 AM
AbbVie (ABBV) And Principia Biopharma Announce Collaboration On Oral Immunoproteasome Inhibitors 6/13/2017 7:48:08 AM
Synlogic Meets First Discovery Milestone In Partnership With AbbVie (ABBV) 6/7/2017 7:34:10 AM
AbbVie (ABBV) Testosterone Gel Faces Scrutiny As First Trial Begins 6/7/2017 6:45:51 AM
AbbVie (ABBV)'s RA Drug Meets All Primary And Secondary Endpoints In Phase III Study 6/7/2017 6:40:49 AM
AbbVie (ABBV) Release: New Data Presented At ASCO 2017 Finds IMBRUVICA (Ibrutinib) May Offer A More Targeted Approach To Chronic Lymphocytic Leukemia (CLL) Treatment Than Chemotherapy Agent Chlorambucil In Treatment-Naïve Patients 6/5/2017 8:37:33 AM
AbbVie (ABBV) Release: Long-Term IMBRUVICA (ibrutinib) Efficacy And Safety Data At ASCO 2017 Show Sustained Survival Rates In Up To Four Years In Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those With High-Risk Disease 6/5/2017 7:01:03 AM
AbbVie (ABBV) Presents Pivotal Phase III Data On Investigational Treatment Elagolix At The World Congress On Endometriosis 5/18/2017 6:39:55 AM